Biopharma
- اسفند- 1396 -4 اسفنددیگر
?Another $145 Million For PDL BioPharma
Summary Current market capitalization is ~$375m. Ongoing litigation between PDL BioPharma and Wellstat could result in a payment to PDLI of up to $145m. Case…
-- بیشتر بخوانید -- - بهمن- 1396 -30 بهمن
A personalized MS treatment built from skin stem cells
A personalized MS treatment built from skin stem cells Progressive forms of multiple sclerosis occur when immune cells called microglia attack the central nervous system,…
-- بیشتر بخوانید -- - 21 بهمن
Kite, Sangamo Launch Up-to-$3B+ Cancer Cell Therapy Partnership
Kite, Sangamo Launch Up-to-$3B+ Cancer Cell Therapy Partnership Kite, a Gilead Company, will use Sangamo Therapeutics’ zinc finger nuclease (ZFN) gene-editing technology platform in a…
-- بیشتر بخوانید -- - 1 بهمندیگر
BGI Genomics Purchases 10 PacBio Sequel Systems
BGI Genomics has agreed to purchase an additional 10 Sequel® System sequencers from Pacific Biosciences (PacBio) of California for an undisclosed price, PacBio said today.PacBio…
-- بیشتر بخوانید -- - دی- 1396 -29 دیدیگر
Strongbridge Biopharma:Are There Further Upsides To This Stellar Grower?
Summary Data for the phase 3 trials (SONICS and LOGICS) studying COR-003 (Recorlev) as the treatment for Cushing’s syndrome will be posted this year. Recorlev…
-- بیشتر بخوانید -- - 11 دیدیگر
Can-Fite Biopharma: Recent Positive Newsflow Not Reflected In Share Price
Summary Can-Fite is progressing well with its lead product candidate. The company has several milestones in 2018. Cash position is weak. Can-Fite Biopharma (CANF) is…
-- بیشتر بخوانید -- - 3 دیدیگر
Top 25 Biopharma IPOs of 2017
Denali Therapeutics showed just how healthy the initial public offering (IPO) market has been, as 2017 comes to a close. The South San Francisco, CA–based…
-- بیشتر بخوانید -- - آذر- 1396 -18 آذردیگر
Cue Biopharma Proposes $60 Million IPO Terms
Summary Cue Biopharma has filed terms for its IPO of up to $60 million. The firm is preparing to enter Phase 1 trials for its…
-- بیشتر بخوانید -- - 5 آذر
(Gastrointestinal Pioneering To Push Red Hill Biopharma Over Hill (Part 1
Summary Despite recent static of dilution missteps and developmental distractions of small-market products, RedHill’s path will ultimately rely on the development of two gastrointestinal drugs.…
-- بیشتر بخوانید --
